XBiotech Business Summary

XBiotech Inc. (XBIT) is a clinical-stage biopharmaceutical company utilizing a proprietary "True Human" antibody platform to discover and develop therapies derived from natural human immunity. The company’s business model is centered on the high-value licensing and divestiture of its antibody candidates, a strategy highlighted by its landmark $750 million sale of bermekimab to Janssen Pharmaceuticals in 2019. Currently a pre-revenue entity, XBiotech focuses its research and development on three primary segments: oncology, inflammatory diseases, and infectious diseases, with lead candidates like Natrunix and Hutrukin targeting advanced pancreatic cancer and ischemic stroke, respectively. Within the competitive landscape, XBiotech faces direct pressure from biotherapeutic developers such as Agenus Inc., Omeros Corporation, and Inovio Pharmaceuticals. It distinguishes itself by exclusively using antibodies cloned from human donors, aiming for superior safety profiles compared to the synthetic or humanized alternatives produced by its peers. The company was founded by John Simard, a seasoned biotech executive with a pedigree including the co-founding of MannKind Corporation and research collaborations at the Amgen Research Institute. As of February 2026, the leadership team is led by Dr. Sushma Shivaswamy, who serves as the Interim Chief Executive Officer and Chief Scientific Officer following Simard’s transition to Chairman of the Board in late 2025. Dr. Shivaswamy, a molecular biologist with the firm since 2009, oversees all technical operations and GMP manufacturing. The executive team is further supported by Angela Hu, Director of Finance, and a distinguished Board of Directors that includes immunology pioneer Dr. Tak W. Mak and academic medicine leader Dr. Thomas Kündig. XBiotech’s investor base is characterized by significant insider ownership and institutional support from major entities such as The Vanguard Group and BlackRock, reflecting a stable long-term commitment to its natural immunity platform.